UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System
Alcon Research, LLC · Decision date Sep 30, 2026
What did the FDA decide?
FDA recorded a 30-Day Notice decision (OK30) dated 2026-09-30 for P230012/S012, a supplement to the UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System, submitted by Alcon Research, LLC. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier. The recorded scope covers three manufacturing changes: an alternate supplier for UNIFEYE screen and pad printing operations, an alternate third-party supplier of ink and additive for printed components, and an alternate third-party supplier for machining and passivating the Valve Seat component.
This action concerns the manufacturing supply chain for the delivery system rather than a new approval of the gas or the complete system. The device category is gases used within the eye to place pressure on a detached retina, with ophthalmic specialty and product code LPO. No supporting documents were included in the source record, so the review basis, any testing performed and whether labeling changed remain unknown.
The OK30 code is reported as recorded; its precise administrative meaning is not defined in the source data and is not interpreted here.
FDA approval order statement
Approval of implementing the following manufacturing changes: 1) Alternate supplier for the UNIFEYE screen and pad printing operations; 2) Alternate ink and additive third-party supplier for the UNIFEYE printed components; 3) Alternate third-party supplier to perform the machining and passivating processes for the Valve Seat component.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Sep 30, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230012/S012
- Regulatory pathway
- PMA supplement
- Applicant
- Alcon Research, LLC
- Product code
- LPO
- Decision code
- OK30
- Decision date
- Sep 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Gases used within eye to place pressure on detached retina.
- Applicant
- Alcon Research, LLC
- Product code
- LPO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230012. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230012 · Original PMA
UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System, UNIPURE SF6 Ophthalmic Gas in the UNIPEXY Gas Delivery Sy
P230012/S012 received
Application receipt date recorded by FDA.
P230012/S012 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P230012. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230012
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Research, LLC | PMA approval | Aug 26, 2024 | FDA |
Explore the linked device profile
Other records with product code LPO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Research, LLC | PMA supplement | Sep 30, 2026 | FDA | |
| Alcon Research, LLC | PMA approval | Jul 2, 2024 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Alcon Research, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 20511 Lake Forest Dr., Lake Forest, CA, 92630
Sources and methodology
- Original FDA record: P230012/S012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

